JIN MEDICAL INTERNATIONAL LTD. (Class A) (ZJYL) 12-Month Stock Forecast & Price Target Cone

ZJYL scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 9 / 20. this pillar reflects ROIC of 0% and FCF yield of -1.27%. Investor implication: the business is not currently generating a return on invested capital or positive free cash flow, so there is no cash-yield cushion supporting the current price.
• Whale 13F Flow: 3 / 20. this pillar measures institutional accumulation and options positioning and scored near the bottom of its range. Investor implication: the rating's flow inputs show little evidence of institutional conviction.
• Insider Conviction: 6 / 20. this pillar covers SEC Form 4 and Congressional PTR cluster flow. Investor implication: insider signal is weak in the rating's inputs.
• Macro Regime Fit: 5 / 20. beta is 1.0 and sector sensitivity is a factor. Investor implication: the rating does not credit the stock with a favorable macro-regime profile.
• Forensic Balance Sheet: 13 / 20. Altman Z is 2.5, Piotroski F is 4/9, and Debt/Equity is 0.5. Investor implication: this is the highest-scoring pillar, indicating the balance sheet is the relative strength, though the Piotroski score of 4/9 signals mixed financial-health indicators.

Taken together, the rating frames a stock whose balance sheet is comparatively the least-weak element while its cash generation, institutional flow, and macro fit are all weak. Valuation tradeoffs are visible in the market data: EV/EBITDA is 47.1 which sits alongside an operating margin of 2.9% and a net margin of 5.8%, so the multiple is not supported by strong operating profitability in the reported figures. Upside drivers would need to come from improving cash conversion, which the FCF yield and recent FCF history do not yet show.

. Per the recent news wire, the company's products are exported to more than 90 countries and regions, and the company manufactures wheelchairs, with dealers discussing its new models.

Revenue declined from $23.5M in FY 2024 to $20.7M in FY 2025, and operating income fell from $3.6M to $0.6M over the same period. Net income of $1.2M in FY 2025 exceeded operating income of $0. Free cash flow was negative in both FY 2025 (-$3.7M) and FY 2024 (-$1.4M) after $3.1M in FY 2023. Per the market data, gross margin is 29.2%, operating margin 2.9%, and net margin 5.8%, with ROIC at 0%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 4/9; the Debt/Equity ratio is 0.

• 🐂 Primary Bull Case: The balance sheet is the RQD's strongest pillar, with an Altman Z of 2.5 and a Debt/Equity ratio of 0.5, and the Kangma transfer avoids new share issuance. With Fundamental Cash Engine at 9/20 (ROIC —, FCF yield -1.27%) and Institutional Whale Flow at 10/20, sustained execution supports upside toward the top of the $1.53 – $8.48 52-week range.
• 🐻 Primary Bear Case: Free cash flow was negative in FY 2025 and FY 2024, ROIC is 0%, revenue fell from $23.5M to $20.7M, and the RQD rates the stock a Roarable Sell. Investors must weigh current valuation and 47.1x EV/EBITDA against 2.9% operating margins and a 1.00 macro beta if sector demand softens.

The main 2nd-order watch item an investor can draw from the provided data is the dependence on the Kangma equity transfer outcome referenced in the news wire, since the company's stated avoidance of substitute share issuance bears on dilution. Investors should also monitor whether declining revenue and operating income continue, given the negative FCF in the two most recent periods.

• Key Question #1: What are the cash and debt balances, since both are listed as N/A in the financial history?
• Key Question #2: What explains net income of $1.2M exceeding operating income of $0.6M in FY 2025?
• Key Question #3: What is the terms and timing of the Kangma equity transfer, and what is its effect on share count?